NCT00196729View on ClinicalTrials.gov

Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration

PHASE3CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

December 31, 2001

Study Completion Date

September 30, 2003

Conditions
Thyroid Neoplasms
Interventions
DRUG

Thyrogen + Radioiodine (131I)

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00196729 - Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration | Biotech Hunter | Biotech Hunter